Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

Sarah A. Holstein, Zaid Al-Kadhimi, Luciano J. Costa, Theresa Hahn, Parameswaran Hari, Jens Hillengass, Allison Jacob, Nikhil C. Munshi, Stefania Oliva, Marcelo C. Pasquini, Qian Shi, Edward A. Stadtmauer, Stephanie L. Waldvogel, Philip L. McCarthy

Research output: Contribution to journalReview article

Abstract

The third annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was held on November 29, 2018, at the American Society of Hematology (ASH) annual meeting. This workshop featured the latest research focused on minimal residual disease (MRD) assessment and immune profiling (IP) in myeloma as well as discussion of the statistical and regulatory issues intrinsic to the development of MRD as a surrogate endpoint. In this report, we provide a summary of the workshop and focus on the integration of MRD and IP assessment into trial design and clinical practice.

Original languageEnglish (US)
Pages (from-to)e7-e15
JournalBiology of Blood and Marrow Transplantation
Volume26
Issue number1
DOIs
StatePublished - Jan 2020

Fingerprint

Residual Neoplasm
Bone Marrow
Clinical Trials
Transplants
Education
Biomarkers
Research

Keywords

  • CAR T cell
  • Endpoint
  • Immune profiling
  • Minimal residual disease
  • Multiple myeloma

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. / Holstein, Sarah A.; Al-Kadhimi, Zaid; Costa, Luciano J.; Hahn, Theresa; Hari, Parameswaran; Hillengass, Jens; Jacob, Allison; Munshi, Nikhil C.; Oliva, Stefania; Pasquini, Marcelo C.; Shi, Qian; Stadtmauer, Edward A.; Waldvogel, Stephanie L.; McCarthy, Philip L.

In: Biology of Blood and Marrow Transplantation, Vol. 26, No. 1, 01.2020, p. e7-e15.

Research output: Contribution to journalReview article

Holstein, SA, Al-Kadhimi, Z, Costa, LJ, Hahn, T, Hari, P, Hillengass, J, Jacob, A, Munshi, NC, Oliva, S, Pasquini, MC, Shi, Q, Stadtmauer, EA, Waldvogel, SL & McCarthy, PL 2020, 'Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling', Biology of Blood and Marrow Transplantation, vol. 26, no. 1, pp. e7-e15. https://doi.org/10.1016/j.bbmt.2019.09.015
Holstein, Sarah A. ; Al-Kadhimi, Zaid ; Costa, Luciano J. ; Hahn, Theresa ; Hari, Parameswaran ; Hillengass, Jens ; Jacob, Allison ; Munshi, Nikhil C. ; Oliva, Stefania ; Pasquini, Marcelo C. ; Shi, Qian ; Stadtmauer, Edward A. ; Waldvogel, Stephanie L. ; McCarthy, Philip L. / Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. In: Biology of Blood and Marrow Transplantation. 2020 ; Vol. 26, No. 1. pp. e7-e15.
@article{c53fcbc238974704b145a567a9d2c46a,
title = "Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling",
abstract = "The third annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was held on November 29, 2018, at the American Society of Hematology (ASH) annual meeting. This workshop featured the latest research focused on minimal residual disease (MRD) assessment and immune profiling (IP) in myeloma as well as discussion of the statistical and regulatory issues intrinsic to the development of MRD as a surrogate endpoint. In this report, we provide a summary of the workshop and focus on the integration of MRD and IP assessment into trial design and clinical practice.",
keywords = "CAR T cell, Endpoint, Immune profiling, Minimal residual disease, Multiple myeloma",
author = "Holstein, {Sarah A.} and Zaid Al-Kadhimi and Costa, {Luciano J.} and Theresa Hahn and Parameswaran Hari and Jens Hillengass and Allison Jacob and Munshi, {Nikhil C.} and Stefania Oliva and Pasquini, {Marcelo C.} and Qian Shi and Stadtmauer, {Edward A.} and Waldvogel, {Stephanie L.} and McCarthy, {Philip L.}",
year = "2020",
month = "1",
doi = "10.1016/j.bbmt.2019.09.015",
language = "English (US)",
volume = "26",
pages = "e7--e15",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

AU - Holstein, Sarah A.

AU - Al-Kadhimi, Zaid

AU - Costa, Luciano J.

AU - Hahn, Theresa

AU - Hari, Parameswaran

AU - Hillengass, Jens

AU - Jacob, Allison

AU - Munshi, Nikhil C.

AU - Oliva, Stefania

AU - Pasquini, Marcelo C.

AU - Shi, Qian

AU - Stadtmauer, Edward A.

AU - Waldvogel, Stephanie L.

AU - McCarthy, Philip L.

PY - 2020/1

Y1 - 2020/1

N2 - The third annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was held on November 29, 2018, at the American Society of Hematology (ASH) annual meeting. This workshop featured the latest research focused on minimal residual disease (MRD) assessment and immune profiling (IP) in myeloma as well as discussion of the statistical and regulatory issues intrinsic to the development of MRD as a surrogate endpoint. In this report, we provide a summary of the workshop and focus on the integration of MRD and IP assessment into trial design and clinical practice.

AB - The third annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was held on November 29, 2018, at the American Society of Hematology (ASH) annual meeting. This workshop featured the latest research focused on minimal residual disease (MRD) assessment and immune profiling (IP) in myeloma as well as discussion of the statistical and regulatory issues intrinsic to the development of MRD as a surrogate endpoint. In this report, we provide a summary of the workshop and focus on the integration of MRD and IP assessment into trial design and clinical practice.

KW - CAR T cell

KW - Endpoint

KW - Immune profiling

KW - Minimal residual disease

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=85073734108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073734108&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2019.09.015

DO - 10.1016/j.bbmt.2019.09.015

M3 - Review article

C2 - 31526843

AN - SCOPUS:85073734108

VL - 26

SP - e7-e15

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 1

ER -